23/10/2023Published by Fondazione Gianni Bonadonna at 23/10/2023Categories Events UncategorizedIpilimumab with or without nivolumab in refractory metastatic melanoma
16/10/2023Published by Fondazione Gianni Bonadonna at 16/10/2023Categories Events UncategorizedThe analysis of thousands of cancer and normal tissue gene expression profiles can guide clinical development of antibody-drug coniugates in the right patient population
09/10/2023Published by Fondazione Gianni Bonadonna at 09/10/2023Categories Events UncategorizedNeratinib, fulvestrant and trastuzumab in HER2-mutant metastatic breast cancer
02/10/2023Published by Fondazione Gianni Bonadonna at 02/10/2023Categories Events UncategorizedSelpercatinib in thyroid and other tumors
25/09/2023Published by Fondazione Gianni Bonadonna at 25/09/2023Categories Events UncategorizedA relevant role for Tau protein in cancer
18/09/2023Published by Fondazione Gianni Bonadonna at 18/09/2023Categories Events UncategorizedSHP2 inhibition to overcome resistance to targeted therapies
11/09/2023Published by Fondazione Gianni Bonadonna at 11/09/2023Categories Events UncategorizedDostarlimab in primary advanced or recurrent endometrial cancer
08/09/2023Published by Michele Tartaglione at 08/09/2023Categories Events UncategorizedIs it possible to predict the efficacy of immunotherapy in triple-negative breast cancer?
04/09/2023Published by Fondazione Gianni Bonadonna at 04/09/2023Categories Events UncategorizedAtezolizumab after chemotherapy in resected non-small cell lung cancer
